Member Info for pomander

Now you have lost me !

Bignose- not sure that I yet adequately understand why there is even a potential issue with this to be in a position to ask a sensible question!

I don't believe the PEBEQ being flawed has ever been an issue. Its within the FDA gudeleones and has been discussed with the FDA. I don't think they are relying on curiosity and I don't think further delays or a complete impasse is inevitable. If there were truoble at mill, the dumbest thing in my view would be to make the questionnaire available now. If anything, I would speculate its release as being super positive indicator that all was on track, as it is the first step to start raising awareness ahead of the US launch. As always time will tell.

ProfZ - RP is not on the list of designated seciruties eligible for short selling on the HKSE. So illegal Again mildly supportive of my view that a stake was taken post UK launch as traders typically like to short sell.

Bignose - so I gather and you are not alone.

Guess you don't subscribe to alq's FDA Bothersome questionnaire theory nor single EU territory launch ! Wonder how lonely men were in the UK over Xmas ?

That's correct for me Escovido, but many traders in HK do, so the charts are relevant in that regard for me. Good to see sustained higher volumes going through now. Interest/ awareness picking up.

I am not going to knock the article, although there are some very obvious inaccuracies, but I am fed up with this two shots at goal argument. Two shots at goal from the half way line are not comparable with two shots at goal from the penalty spot.

Alq- On this aptly named Bothersome Questionnaire, thanks for alerting us non pharma folk to a potential catastrophic issue with the FDA, but please do bear with me, for as I see things the dumbest course of action you could take is to put the Bothersome Questionnaire into the public domain if it were flawed in any way. Intuitively, the creation of the website at this time would indicate to me that everything was going swimmingly well with the FDA and no doubt it has also been done on the advice of those pharma consultant specialist expert types that are always right. Part of me also keeps thinking, are we over engineering what is a relatively simply compound with few side affects (if any) for a condition which is very widespread (whatever cinical definition you choose to adopt) and lacking an approved option. Intrigued by your knowledge on the original trademark name.

I am afraid 008 prtocol means little to me - I just saw it as a website promoting a questionnaire, the contents of which have been agreed with the FDA to assist clinician's and potential suffers to make a determniation of whether or not they suffered form PE and might bebefit from a treatment being developed by Ple. If there were trouble at mill, charging 5 bucks for the privilege would seem a little dumb. I saw it as just laying some groundwork to begin the process of differentiating Fortacin from other inferior and non approved prouducts. I see the the Questionnaire trademark went from Statemnet of Use to Examiner status on the 5th Jan 2018 (Statemenet of Use Processing Complete) but have no idea what (if any) is the siginificance of this.

Thanks for that, I must say the website launch appears simply to be a positive initial step in raising awareness of PE amongst both healthcare professionals & potential sufferers, ahead of the eventual launch of Fortacin. Arn't the PRO and PEBEQ quite different things altogether, and the RP presentation (Oct 2017) maintains the original timeframes and states Multiple clinical endpoints IELT and patient reported outcome (PRO) measures all demonstrate clinical and statistical significance. Are you suggesting that this information is mis-leading ?

What's the difference from 70 p (Sept 2016) to 40p Performance to date looks remarkably similar to me. Ple went from 1.5 pence to 21 pence on AIM.

https://www.youtube.com/watch?v=LKwja-t4QMI 30 seconds in - marvellous fraudian slip !

Ok- FF was previopusly called Kuala and before that China Growth Opportunities, both mning companise with Dattels coming on board when it became Kuala. Kuala then morphed into FF to invest in bio pharma, a l RP, at which point Dattels must have resigned post your RNS with JM becoming Chairman for y/e Marc 2017 and in which he said (not mirrored by RP). The Diabetic Boot Company Limited DBC, which trades under the name �Pulseflow�, has developed a new form of diabetic friendly footwear with integrated offloading capabilities and the patented Pulseflow technology which aids in the promotion of blood flow and improved circulation in one product. In April 2016 DBC raised additional capital from; among others Regent Pacific Group Limited in which Jim Mellon is a director and has a 21% shareholding. This additional capital was dependent on DBC achieving certain milestones which it has not. On 6 October 2016, Life Science Developments Limited (�Life�), a company listed on the AIM market and in which Jim Mellon is a director, announced that it had entered into a non-binding term sheet to acquire 100% of DBC for new shares in Life however after the year end Life announced that the acquisition was taking longer than anticipated to conclude. DBC has successfully obtained short term debt finance and a convertible security in which Fast Forward did not participate It is disappointing that DBC has missed key milestones and to see the value of the company not increase as expected. The major challenge for the DBC board is to successfully navigate its current funding issues. That said, I am optimistic about this investment and I will continue to closely monitor the efforts of DBC and its major shareholders to deliver value by commercialising its key product.

I don't see Dattels at FFWD- he resigned some time ago from RP of course. MW never been made a director at RP as originally indicated, which I thought might have been to enable him to remain unconflicted from recommending any bid for Ple to RP shareholders. Should get a clearer picture - would expect that wall of money to arrive ahead of the EU launch.

Bignose- JG has no pharma expertise -its all JM and his advisers. The Borad are just figureheads now, that do very little but make up the numbers. Dattels was the mining wizz and he has fgone. RP shows no signs of capital raising to diversify / expand its pharma portfolio, its stated aim- seems all is riding on Fortacin. Perhaps RG should be questioned on that? Andy Smith who was at ManBio was one of JM's pharma specialists but he has now left. DBC was subject of a R/T by LIFFE but that was de-listed before it could raise sufficient funding. Right now JM supports DBC personally with a �2m loan (from memory). I agree an update should be provided by JG.

From a quick look, New Wave Ventures took a stake of �2m back in December 2011. A 5x exit multiple in part shares, does appear a little light for an early stage bio seeder. This also caught my eye on the deal - seems quite generous to Discuva directors and eligible employees. Under a collaboration agreement that Discuva has with F. Hoffmann - La Roche Limited ('Roche'), Roche is obligated to pay specified development, commercialisation and sales milestone payments related to any compound developed under the platform that is or has been optioned by Roche. Summit is obligated to pay to Discuva shareholders one-half of the economic benefit of any such payments received from Roche. Separately, certain employees, former employees and former directors of Discuva are eligible for payments from Discuva based on specified development and clinical milestones related to proprietary product candidates developed under the platform.

The timing is difficult to fathom, the last spike was circa 70m post the manufacturing update. Looks a bit leaky to me. Oh well, should be back above 73 cents toute de suite.

Sorry, but either dumb or taking the preverbrial, but clearly you should not be invested in RP, and perhaps in any share. Ticker, ticker , ticker

Likewise GMCC - I hope 2018 will be a good year for you.